What is the current stock price of Rigel Pharmaceuticals, Inc. (RIGL)?

As of the latest market data, Rigel Pharmaceuticals, Inc. (RIGL) is trading at $29.20. The stock has seen a loss of -4.29% today.

Does Rigel Pharmaceuticals, Inc. (RIGL) pay a dividend?

Based on current data, Rigel Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Rigel Pharmaceuticals, Inc.?

The current market capitalization of Rigel Pharmaceuticals, Inc. (RIGL) is approximately unavailable.

RIGL

Rigel Pharmaceuticals, Inc.·Healthcare

29.20

4.294%(−1.31)

Market Closed

30.99

6.130%(+1.79)

After Hours

Last Updated: — ET

52W L: $16.0552W H: $52.24

RIGL NEWS

seekingalpha.com

2d ago

Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade)

Rigel Pharmaceuticals (RIGL) is upgraded to a speculative Buy as profitability and product momentum improve. Gavreto acquisition has materially boosted revenue and is valued at ~$245M NPV, about half RIGL's market cap. Tavalisse demand surged, carving a defensible niche in ITP; Rezlidhia seeks expansion beyond AML.

prnewswire.com

4d ago

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

prnewswire.com

Mar 31

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

Pralsetinib induced robust and durable responses with a manageable safety profile, reinforcing the benefits of selective RET inhibitors in treating RET fusion-positive NSCLC SOUTH SAN FRANCISCO, Calif., March 31, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication of the final data from the Phase 1/2 ARROW study evaluating pralsetinib for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) in the Journal of Clinical Oncology.

defenseworld.net

Mar 29

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The

seekingalpha.com

Mar 10

Rigel Pharmaceuticals: Growing Where It Matters

Rigel Pharmaceuticals maintains strong sales momentum across its three approved targeted therapies, justifying a continued Buy rating. RIGL trades at a low P/E of ~7 despite robust 2025 revenue growth and positive cash flow, suggesting undervaluation relative to peers. Pipeline risk remains, as R289 for lower-risk MDS is still early-stage and highly speculative, with no imminent label expansions for existing drugs.

seekingalpha.com

Mar 3

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript

Company Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

162

IPO Date

2000-11-29

Beta

1.27

Websitewww.rigel.com↗